Literature DB >> 24114193

Current sickle cell disease management practices in Nigeria.

N Galadanci1, B J Wudil, T M Balogun, G O Ogunrinde, A Akinsulie, F Hasan-Hanga, A S Mohammed, M O Kehinde, J A Olaniyi, I N Diaku-Akinwumi, B J Brown, S Adeleke, O E Nnodu, I Emodi, S Ahmed, A O Osegbue, N Akinola, H I O Opara, S A Adegoke, J Aneke, A D Adekile.   

Abstract

BACKGROUND: Although Nigeria has the highest burden of sickle cell disease (SCD) worldwide, there is still variable and poor utilisation of standard-of-care practices for SCD patients in the country.
METHODS: This was a questionnaire survey of doctors in some dedicated SCD clinics in Nigeria in order to document the facilities available and common management practices.
RESULTS: There were responses from 18 clinics based in 11 institutions. The number of patients being followed in each centre ranged from 15 to approximately 11 000. All clinics provided malaria prophylaxis and folic acid routinely to their patients. Only eight clinics prescribe penicillin prophylaxis. Eight prescribe hydroxyurea to patients who can afford it when indicated. All of the centres except three have electronic cell counters, but all had access to haemoglobin electrophoresis. Three had high-performance liquid chromatography machines installed but none was being routinely used. One institution had a functioning molecular biology laboratory. There is no official newborn screening programme in the country. All had access to microbiology and chemistry laboratories. Nine institutions had CT, six had MRI and three had transcranial Doppler facilities.
CONCLUSION: The care available for SCD in Nigeria is still suboptimal and there is an urgent need for concerted effort to tackle the problem, but to make a significant impact on the burden of the disease would require more focus at the primary care level. Some steps to achieving this are outlined.

Entities:  

Keywords:  Future projections; Management; Nigeria; Sickle cell disease

Mesh:

Substances:

Year:  2013        PMID: 24114193      PMCID: PMC6281355          DOI: 10.1093/inthealth/iht022

Source DB:  PubMed          Journal:  Int Health        ISSN: 1876-3405            Impact factor:   2.473


  31 in total

1.  High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya.

Authors:  Charlotte F McAuley; Clare Webb; Julie Makani; Alexander Macharia; Sophie Uyoga; Daniel H Opi; Carolyne Ndila; Antony Ngatia; John Anthony G Scott; Kevin Marsh; Thomas N Williams
Journal:  Blood       Date:  2010-06-08       Impact factor: 22.113

2.  Implementation of the STOP protocol for Stroke Prevention in Sickle Cell Anemia by using duplex power Doppler imaging.

Authors:  A J Malouf; J E Hamrick-Turner; M C Doherty; G S Dhillon; R V Iyer; M G Smith
Journal:  Radiology       Date:  2001-05       Impact factor: 11.105

3.  Pneumococcal prophylaxis for children with sickle cell disease in Africa.

Authors:  M de Montalembert; V Brousse; J-R Zahar
Journal:  Arch Dis Child       Date:  2008-08       Impact factor: 3.791

4.  Acute illness in Nigerian children with sickle cell anaemia.

Authors:  O Akinyanju; A O Johnson
Journal:  Ann Trop Paediatr       Date:  1987-09

Review 5.  Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature.

Authors:  E Barrett-Connor
Journal:  Medicine (Baltimore)       Date:  1971-03       Impact factor: 1.889

6.  Cerebrovascular accidents in sickle cell disease: rates and risk factors.

Authors:  K Ohene-Frempong; S J Weiner; L A Sleeper; S T Miller; S Embury; J W Moohr; D L Wethers; C H Pegelow; F M Gill
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

7.  Bacteraemia in homozygous sickle cell disease in Africa: is pneumococcal prophylaxis justified?

Authors:  M E Kizito; E Mworozi; C Ndugwa; G R Serjeant
Journal:  Arch Dis Child       Date:  2006-03-10       Impact factor: 3.791

Review 8.  Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease.

Authors:  F M Gill; L A Sleeper; S J Weiner; A K Brown; R Bellevue; R Grover; C H Pegelow; E Vichinsky
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

Review 9.  Sickle cell disease and the kidney.

Authors:  Jon I Scheinman
Journal:  Semin Nephrol       Date:  2003-01       Impact factor: 5.299

Review 10.  The spleen in the sickling disorders: an update.

Authors:  Rana Khatib; Raja Rabah; Sharada A Sarnaik
Journal:  Pediatr Radiol       Date:  2008-11-11
View more
  37 in total

1.  Impact of sickle cell trait on the thrombotic risk associated with non-O blood groups in northern Nigeria.

Authors:  Sagir G Ahmed; Modu B Kagu; Umma A Ibrahim; Audu A Bukar
Journal:  Blood Transfus       Date:  2015-05-27       Impact factor: 3.443

2.  Translational Genomics in Low- and Middle-Income Countries: Opportunities and Challenges.

Authors:  Fasil Tekola-Ayele; Charles N Rotimi
Journal:  Public Health Genomics       Date:  2015-06-26       Impact factor: 2.000

3.  Knowledge and awareness of personal sickle cell genotype among parents of children with sickle cell disease in southeast Nigeria.

Authors:  O U Ezenwosu; B F Chukwu; A N Ikefuna; A T Hunt; J Keane; I J Emodi; E E Ezeanolue
Journal:  J Community Genet       Date:  2015-04-14

4.  Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.

Authors:  Shehu U Abdullahi; Michael R DeBaun; Lori C Jordan; Mark Rodeghier; Najibah A Galadanci
Journal:  Pediatr Neurol       Date:  2019-01-17       Impact factor: 3.372

5.  Prevalence of Sickle Cell Trait and Reliability of Self-Reported Status among Expectant Parents in Nigeria: Implications for Targeted Newborn Screening.

Authors:  Amanda R Burnham-Marusich; Chinenye O Ezeanolue; Michael C Obiefune; Wei Yang; Alice Osuji; Amaka G Ogidi; Aaron T Hunt; Dina Patel; Echezona E Ezeanolue
Journal:  Public Health Genomics       Date:  2016-09-10       Impact factor: 2.000

Review 6.  Folate supplementation in people with sickle cell disease.

Authors:  Ruchita Dixit; Sowmya Nettem; Simerjit S Madan; Htoo Htoo Kyaw Soe; Adinegara B L Abas; Leah D Vance; Patrick J Stover
Journal:  Cochrane Database Syst Rev       Date:  2016-02-16

7.  Hydroxyurea therapy in adult Nigerian sickle cell disease: a monocentric survey on pattern of use, clinical effects and patient's compliance.

Authors:  Ademola Samson Adewoyin; Omokiniovo Sunday Oghuvwu; Omolade Augustina Awodu
Journal:  Afr Health Sci       Date:  2017-03       Impact factor: 0.927

8.  Fixed Low-Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Anemia in Nigeria.

Authors:  Bamidele O Tayo; Titilola S Akingbola; Santosh L Saraf; Binal N Shah; Chinedu A Ezekekwu; Omowunmi Sonubi; Lewis L Hsu; Richard S Cooper; Victor R Gordeuk
Journal:  Am J Hematol       Date:  2018-05-14       Impact factor: 10.047

9.  Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial.

Authors:  Shehu U Abdullahi; Binta J Wudil; Halima Bello-Manga; Aisha B Musa; Safiya Gambo; Najibah A Galadanci; Hauwa Aminu; Aliyu Tijjani Gaya; Surayya Sanusi; Musa A Tabari; Aisha Galadanci; Awwal Borodo; Muhammed S Abba; Abdu H Dambatta; Lawal Haliru; Awwal Gambo; Holly Cassell; Mark Rodeghier; Djamila L Ghafuri; Brittany V Covert Greene; Kathleen Neville; Adetola A Kassim; Fenella Kirkham; Edwin Trevathan; Lori C Jordan; Muktar H Aliyu; Michael R DeBaun
Journal:  Pediatr Hematol Oncol       Date:  2020-11-25       Impact factor: 1.969

10.  Comparison of patients from Nigeria and the USA highlights modifiable risk factors for sickle cell anemia complications.

Authors:  Titilola S Akingbola; Bamidele O Tayo; Babatunde Salako; Jennifer E Layden; Lewis L Hsu; Richard S Cooper; Victor R Gordeuk; Santosh L Saraf
Journal:  Hemoglobin       Date:  2014-06-18       Impact factor: 0.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.